Signoriello, E., Lus, G., Bonavita, S., Lanzillo, R., Saccà, F., Landi, D., Frau, J., Baroncini, D., Zaffaroni, M., Maniscalco, G. T., Curti, E., Sartori, A., Cepparulo, S., Marfia, G. A., Nicoletti, C. G., Carotenuto, A., Nociti, V., Caleri, F., Sormani, M. P., & Signori, A. (2022). switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. Multiple sclerosis, 28, 93–101. http://access.bl.uk/ark:/81055/vdc_100138853100.0x000009